PHS
TEVA icon

PFM Health Sciences’s Teva Pharmaceuticals TEVA Stock Holding History

PFM Health Sciences’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,713,000
Closed -$1.01M – 87
2015
Q3 		$1.01M Buy
+2,713,000
New +$176M 0.03% 68
2014
Q2 		– Sell
-404,100
Closed -$570K – 77
2014
Q1 		$570K Buy
+404,100
New +$18.7M 0.01% 72

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PFM Health Sciences's TEVA Position: Q4 2025 in Review

PFM Health Sciences sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 356,818 shares — an estimated $7.21M sold.

PFM Health Sciences first reported a position in TEVA in Q1 2014 and held it in 12 quarters. The position peaked at $184M in Q2 2014. 630 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • PFM Health Sciences reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • PFM Health Sciences sold 356,818 Teva Pharmaceuticals shares in Q4 2025, an estimated $7.21M.
  • PFM Health Sciences first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 12 quarters.
  • PFM Health Sciences's Teva Pharmaceuticals position peaked at $184M in Q2 2014.
  • 630 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on PFM Health Sciences's 13F filing for Q4 2025, filed 17 Feb 2026.